Cystic Fibrosis organisations in Australia provide support and services to people with Cystic Fibrosis (CF) and their carers and families. This is complemented by a commitment to research and a quality improvement program focussing on improved clinical care for people with CF.
Every four days a baby is born in Australia with cystic fibrosis (CF) and more than one million Australians are carriers of cystic fibrosis. Cystic Fibrosis Australia (CFA) is committed to improving clinical practice and patient outcomes through its quality improvement programmes and research with the aim of extending life expectancy from 37 to 50 years by 2025.
Cystic Fibrosis is a recessive genetic condition. It primarily affects the lungs and digestive system because of a malfunction in the exocrine system, responsible for producing saliva, sweat, tears and mucus.
In addition to working for a cure, Cystic Fibrosis Australia also provides support and advocacy to improve the lives of people with cystic fibrosis. Get involved by raising awareness about CF, participating in a fundraising event or volunteering.
Cystic Fibrosis Australia has established a consistent approach to advocacy across Australia and is now a subject matter expert for government, industry and the media.
The Australian Cystic Fibrosis Research Trust (ACFRT) is managed by Cystic Fibrosis Australia (CFA). Since 1989 it has funded more than 300 projects valued at over $6,000,000.
Visit the media room to browse through number of resources including media representatives, press releases and reports.
Clinical trials are listed below.
Anti-InfectiveEnrolling Location: Australia
Fungal exposure and fungal-specific IgE in subjects with cystic fibrosis (Australian Cystic Fibrosis Research Trust 2004/052) , protocol number ACTRN12605000156684
Fungal exposure and fungal-specific IgE in subjects with cystic fibrosis (Australian Cystic Fibrosis Research Trust 2004/052)
Age:
Not Specified
Mutation(s):
Not specified
FEV1% Predicted:
Number of Visits:
Length of Participation:
Nutritional-GIActive, not recruiting Location: Australia
Prevalence and predictors of malnutrition and decreased bone density in cystic fibrosis. , protocol number ACTRN12605000426684
Prevalence and predictors of malnutrition and decreased bone density in cystic fibrosis.
>18 years
Nutritional-GIRecruiting Location: Australia
Gastric emptying and malnutrition in adults with cystic fibrosis. , protocol number ACTRN12605000427673
Gastric emptying and malnutrition in adults with cystic fibrosis.
OtherEnrolling Location: Australia
Effect of Positive Expiratory Pressure (PEP) on the duration of the exacerbation-free period in people with cystic fibrosis (CF). , protocol number ACTRN12605000348651
Effect of Positive Expiratory Pressure (PEP) on the duration of the exacerbation-free period in people with cystic fibrosis (CF).
FEV1 within 15% of their best recorded value as an outpatient for the preceding six months
OtherNot yet recruiting Location: Australia
Phase 3, placebo-controlled, parallel group randomised trial of the effect of nebulised hypertonic saline on the length of stay of people hospitalised with acute exacerbations of cystic fibrosis lung disease. , protocol number ACTRN12605000780651
Phase 3, placebo-controlled, parallel group randomised trial of the effect of nebulised hypertonic saline on the length of stay of people hospitalised with acute exacerbations of cystic fibrosis lung disease.
>17 years
Pilot trial of the tolerability of hypertonic saline when delivered by a high-output nebuliser twice or four time daily to people with cystic fibrosis. , protocol number ACTRN12606000053527
Pilot trial of the tolerability of hypertonic saline when delivered by a high-output nebuliser twice or four time daily to people with cystic fibrosis.
No limit
>40% pred.
ObservationalRecruiting Location: Australia - NSW, QLD, SA, VIC, WA
Prevention of Bronchiectasis in Infants with Cystic Fibrosis , protocol number NCT01270074
The general aim of this project is to conduct a randomised, double-blind, placebo-controlled clinical trial of azithromycin to determine whether treatment from infancy is safe and will prevent the onset of bronchiectasis. One hundred and thirty infants will be recruited from CF clinics in Australia and New Zealand and treated from 3 months to three years of age. The outcome will be the proportion with radiologically-defined bronchiectasis at 3 years of age. Safety and mechanistic evaluations will also be undertaken.
Maximum 6 months
ObservationalRecruiting Location: Australia - NSW, QLD, SA
Insulin Deficiency, Early Action , protocol number NCT01100892
Cystic fibrosis (CF) is the most common life-threatening genetic condition affecting Australian children. As well as repeated lung infections, children with CF develop insulin deficiency and eventually diabetes. Te CF-IDEA trial (Cystic Fibrosis - Insulin Deficiency, Early Action) will determine whether starting insulin treatment before the onset of diabetes (earlier than current practice) will improve the health of children with CF by improving body weight and lung function.
5 - 19 Years
CFID1 or CFID2
OtherRecruiting Location: Australia
Does tiotropium bromide lead to bronchodilation in cystic fibrosis? , protocol number ACTRN12605000728639
Does tiotropium bromide lead to bronchodilation in cystic fibrosis?
Evaluation of CF patient perception of symptom improvement following inhaled antibiotic treatment. , protocol number ACTRN12605000602628
Diagnosis of CF and chronic PA infection (defined as cultures positive for PA for > 6 months, including most recent culture). Have adequate understanding of English to give informed consent and follow study procedures. Patient must have completed their most recent course of TOBI or aerosolized tobramycin solution or any other aerosolized antibiotic at least 28 days prior to study entry. Parent/guardian of children 6 to 13 years old must agree to complete the CFQ-R and Global Rating of Change Questionnaires. Patient's physician must have decided to prescribe a 28 day course of TOBI for treatment of clinical symptoms (increased cough, increased sputum production/chest congestion, decreased exercise tolerance, or decreased appetite).
6 years - no stated upper limit